CorMedix Inc (CRMD) FY2025Q3 Earning Prediction

11/12 05:00:00

Pre-Market

CorMedix Inc (CRMD) is set to release its earnings performance on 11/12 05:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 86.02M and an earnings per share (EPS) of 0.48 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueBEAT

86.02M

104.28M

+21.22%

EPSBEAT

0.48

0.57

+18.75%

AI Summary

Report

Attend Webcast

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

CRMD Transcript

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

Unknown11-12

The earnings call summary provides mixed signals. While there are positive aspects such as potential revenue growth from REZZAYO and DefenCath, and expected synergies from the Melinta acquisition, there are concerns about increased operating expenses and lack of clear financial guidance for 2026. The Q&A session reveals some uncertainties, particularly around pricing dynamics post-TDAPA and exact utilization figures for DefenCath. These mixed elements suggest a neutral sentiment, indicating the stock price may remain stable over the next two weeks.

CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Neutral9-10

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

Positive8-8

The earnings call summary reveals strong financial performance, with significant cash flow improvements and decreased marketing expenses. The guidance for DefenCath sales is robust, and the Melinta acquisition offers growth potential, especially with REZZAYO. Despite some uncertainties in integration costs and competitive pressures, the overall sentiment is positive. The Q&A section highlights confidence in growth drivers and minimal concerns about risks. The company's strategic focus on growth and market expansion, along with a positive sales outlook, supports a positive stock price reaction.

Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises

Positive5-6

The earnings call summary highlights strong financial performance with a net income of $20.6M and a significant improvement from a net loss in the previous year. The company's revenue guidance and cash position are robust, with positive feedback from customers on product integration. However, there are operational and clinical development risks noted, but these do not overshadow the strong earnings and optimistic guidance. The Q&A section reveals management's confidence despite some uncertainties. Overall, the positive financial results and guidance suggest a likely stock price increase in the short term.

CRMD Report

Frequently Asked Questions

What is the CorMedix Inc FY2025Q3 Earnings Release Date and Time?

CorMedix Inc (CRMD) is scheduled to release its FY2025Q3 earnings report onNov 12, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for CorMedix Inc FY2025Q3 Revenue and EPS?

Analysts' consensus predicts 86.02M in revenue and an EPS of 0.48 for CorMedix Inc's FY2025Q3.

What Does Intellectia's AI Predict for CorMedix Inc FY2025Q3 Earnings?

Intellectia's exclusive AI algorithms forecast a forCorMedix Inc's FY2025Q3 earnings, with a prediction date of Nov 12, 2025. CorMedix Inc

How Can I Use This Earnings Prediction to Trade CRMD Stock?

Leverage Intellectia's AI forecast to position trades ahead of theNov 12, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like CorMedix Inc FY2025Q3?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!